A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema

Phase 1 Completed 24 enrolled Innovent Biologics (Suzhou) Co. Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

This study is designed as a Multi-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single and multiple intravitreal injections of IBI324 in subjects with DME

Timeline

Start: 2022-08-01
Primary completion: 2023-06-05
Completion: 2023-06-05

Publications

Wang Z, Sun J, Liu K, Tao L, Liu Q, Wu M, Lu S, Deng J, Li L, Qian L, Li X, Sun X. Phase 1 dose-escalation study of IBI324, a VEGF-A/Ang-2 bispecific antibody, for the treatment of diabetic macular oedema. BMJ Open Ophthalmol. 2026 Jan 5;11(1):e002035. doi: 10.1136/bmjophth-2024-002035.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IBI324	Monoclonal antibody	0.5 mg	Intravitreal
Subject	IBI324	Monoclonal antibody	2 mg	Intravitreal
Subject	IBI324	Monoclonal antibody	4 mg	Intravitreal

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema

Summary

Timeline

Publications

Drugs

Indications